Aliases & Classifications for Diabetic Neuropathy

MalaCards integrated aliases for Diabetic Neuropathy:

Name: Diabetic Neuropathy 12 74 53 36 15 37 17
Diabetic Neuropathies 54 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9743
KEGG 36 H01459
ICD9CM 34 250.6
MeSH 43 D003929
NCIt 49 C26748
SNOMED-CT 67 230572002
UMLS 71 C0011882

Summaries for Diabetic Neuropathy

NINDS : 53 Diabetic neuropathy is a peripheral nerve disorder caused by diabetes or poor blood sugar control. The most common types of diabetic neuropathy result in problems with sensation in the feet. It can develop slowly after many years of diabetes or may occur early in the disease. The symptoms are numbness, pain, or tingling in the feet or lower legs. The pain can be intense and require treatment to relieve the discomfort. The loss of sensation in the feet may also increase the possibility that foot injuries will go unnoticed and develop into ulcers or lesions that become infected. In some cases, diabetic neuropathy can be associated with difficulty walking and some weakness in the foot muscles. There are other types of diabetic-related neuropathies that affect specific parts of the body. For example, diabetic amyotrophy causes pain, weakness and wasting of the thigh muscles, or cranial nerve infarcts that may result in double vision, a drooping eyelid, or dizziness. Diabetes can also affect the autonomic nerves that control blood pressure, the digestive tract, bladder function, and sexual organs. Problems with the autonomic nerves may cause lightheadedness, indigestion, diarrhea or constipation, difficulty with bladder control, and impotence.

MalaCards based summary : Diabetic Neuropathy, also known as diabetic neuropathies, is related to microvascular complications of diabetes 1 and diabetic autonomic neuropathy, and has symptoms including sciatica and neuralgia. An important gene associated with Diabetic Neuropathy is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and MAPK signaling pathway. The drugs Granisetron and Histamine have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and spinal cord, and related phenotypes are behavior/neurological and growth/size/body region

KEGG : 36 Diabetic neuropathies (DNs) are nerve damaging disorders caused by diabetes. Diabetic neuropathy broadly comprise generalized symmetric polyneuropathies (acute sensory, chronic sensorimotor, autonomic) and asymmetric (focal and multifocal) neuropathies (cranial, truncal, focal-limb, proximal-motor, coexisting chronic inflammatory demyelinating), which affect all organs and system. Of all types, diabetic sensorimotor polyneuropathy (DSPN), also called distal symmetric neuropathy, is the most typical form. Typical Symptoms vary from person to person, but may include numbness, tingling, pain, or weakness that typically starts in the feet and progresses up the legs. This pattern of neuropathy shows a progressive distal axonopathy. It has been reported that vascular endothelial growth factor A is associated with DNs development and progression.

Wikipedia : 74 Diabetic neuropathy refers to various types of nerve damage associated with diabetes mellitus. Symptoms... more...

Related Diseases for Diabetic Neuropathy

Diseases related to Diabetic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 374)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 33.5 VEGFA NTF3 NGF INS AKR1B1 AGER
2 diabetic autonomic neuropathy 33.2 NTF3 NGF INS EPO AKR1B1 ACE
3 microvascular complications of diabetes 3 32.9 INS AKR1B1 AGER ACE
4 microvascular complications of diabetes 5 32.6 VEGFA SORD SOD2 INS AKR1B1 AGER
5 diabetes mellitus, type i 32.5 VEGFA TLR4 SOD2 LEP INS AKR1B1
6 neuropathy 32.3 VEGFA SCN9A PMP22 NTRK1 NGF ACE
7 diabetes mellitus, noninsulin-dependent 32.1 VEGFA TLR4 NGF LEP INS CAT
8 diabetic polyneuropathy 31.4 VEGFA SOD2 NTF3 NGF INS AKR1B1
9 hyperglycemia 31.4 SORD SOD2 LEP INS CAT AKR1B1
10 mononeuropathy 31.3 TRPV1 PMP22 NGF
11 peripheral vascular disease 31.2 VEGFA INS EPO ACE
12 autonomic neuropathy 31.2 SCN9A NTRK1 NTF3 NGF INS EPO
13 polyneuropathy 31.2 VEGFA PMP22 NGF INS GDNF EPO
14 impotence 31.1 VEGFA INS ACE
15 carpal tunnel syndrome 30.9 VEGFA PMP22 INS ACE
16 sensory peripheral neuropathy 30.7 TRPV1 PMP22 NTRK1 NTF3 NGF CALCA
17 demyelinating polyneuropathy 30.7 PMP22 NGF GDNF
18 vascular disease 30.6 VEGFA TLR4 LEP INS EPO CAT
19 fibromyalgia 30.6 SCN9A NGF LEP CALCA
20 sleep apnea 30.6 VEGFA LEP INS EPO ACE
21 uremia 30.5 LEP INS EPO ACE
22 pain agnosia 30.5 TRPV1 TRPM8 SCN9A NGF CALCA
23 prediabetes syndrome 30.5 LEP INS ACE
24 peripheral artery disease 30.4 VEGFA AGER ACE
25 sleep disorder 30.4 LEP INS ACE
26 diabetic angiopathy 30.4 SOD2 INS CAT AGER
27 neurogenic arthropathy 30.4 NTRK1 NGF INS CALCA
28 complex regional pain syndrome 30.4 SCN9A CALCA ACE
29 cerebrovascular disease 30.3 TLR4 LEP INS AGER ACE
30 diabetic encephalopathy 30.3 NGF INS GDNF CAT
31 ischemia 30.3 VEGFA SOD2 EPO CAT ACE
32 burning mouth syndrome 30.3 TRPV1 SCN9A NGF CALCA
33 algoneurodystrophy 30.2 NGF INS CALCA
34 silent myocardial infarction 30.2 INS ACE
35 apnea, obstructive sleep 30.2 VEGFA LEP INS ACE
36 constipation 30.2 TRPV1 NTF3 INS GDNF CAT CALCA
37 bone resorption disease 30.2 LEP INS CALCA
38 congestive heart failure 30.2 VEGFA INS EPO ACE
39 uremic neuropathy 30.2 TRPM8 PMP22 EPO
40 kidney disease 30.1 LEP INS EPO AKR1B1 AGER ACE
41 arteries, anomalies of 30.1 VEGFA LEP INS ACE
42 trigeminal neuralgia 30.0 TRPV1 SCN9A NGF CALCA
43 cataract 30.0 VEGFA SORD SOD2 LEP INS CAT
44 amyotrophic lateral sclerosis 1 30.0 TLR4 SOD2 NTRK1 NTF3 NGF GDNF
45 duodenal ulcer 30.0 TLR4 INS CAT CALCA
46 motor neuron disease 30.0 VEGFA SOD2 NTF3 INS GDNF CAT
47 diabetes mellitus 29.9 VEGFA TLR4 SORD SOD2 LEP INS
48 hypothyroidism 29.9 VEGFA LEP INS CALCA ACE
49 chronic kidney disease 29.9 VEGFA TLR4 LEP INS EPO ACE
50 respiratory failure 29.8 TLR4 EPO CAT ACE

Graphical network of the top 20 diseases related to Diabetic Neuropathy:



Diseases related to Diabetic Neuropathy

Symptoms & Phenotypes for Diabetic Neuropathy

UMLS symptoms related to Diabetic Neuropathy:


sciatica, neuralgia

MGI Mouse Phenotypes related to Diabetic Neuropathy:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 ACE AGER AKR1B1 GDNF INS LEP
2 growth/size/body region MP:0005378 10.39 ACE AGER AKR1B1 GDNF INS LEP
3 homeostasis/metabolism MP:0005376 10.37 ACE AGER AKR1B1 CAT EPO INS
4 cardiovascular system MP:0005385 10.31 ACE AGER EPO GDNF INS LEP
5 mortality/aging MP:0010768 10.28 ACE AKR1B1 CAT EPO GDNF INS
6 cellular MP:0005384 10.26 AGER CAT EPO GDNF INS LEP
7 immune system MP:0005387 10.26 ACE AGER EPO GDNF INS LEP
8 integument MP:0010771 10.23 AGER EPO INS LEP NGF NTRK1
9 muscle MP:0005369 10.15 AGER EPO GDNF INS LEP NGF
10 nervous system MP:0003631 10.07 GDNF INS LEP NGF NTF3 NTRK1
11 liver/biliary system MP:0005370 10.03 ACE EPO INS LEP SOD2 TLR4
12 neoplasm MP:0002006 9.87 ACE CAT LEP SOD2 TLR4 TRPV1
13 normal MP:0002873 9.85 AGER EPO INS NGF NTF3 NTRK1
14 renal/urinary system MP:0005367 9.7 ACE AGER AKR1B1 GDNF INS LEP
15 vision/eye MP:0005391 9.36 AKR1B1 INS LEP NGF NTF3 NTRK1

Drugs & Therapeutics for Diabetic Neuropathy

Drugs for Diabetic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 291)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
2
Histamine Approved, Investigational Phase 4 51-45-6 774
3
Amitriptyline Approved Phase 4 50-48-6 2160
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
6
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
9
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
10
leucovorin Approved Phase 4 58-05-9 6006 143
11
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
12
Cetirizine Approved Phase 4 83881-51-0 2678
13
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
14
Metformin Approved Phase 4 657-24-9 14219 4091
15
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
16
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
17
Linaclotide Approved Phase 4 851199-59-2 65351
18
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
19
Donepezil Approved Phase 4 120014-06-4 3152
20
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
21
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
22
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
23
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
24
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
25
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051
26
Cobalamin Experimental Phase 4 13408-78-1 6857388
27 Anesthetics Phase 4
28 Pharmaceutical Solutions Phase 4
29 Chelating Agents Phase 4
30 Adjuvants, Immunologic Phase 4
31 Benphothiamine Phase 4
32 Antihypertensive Agents Phase 4
33 Histamine Antagonists Phase 4
34 Anti-Allergic Agents Phase 4
35 Antiemetics Phase 4
36 Histamine H1 Antagonists Phase 4
37
Histamine Phosphate Phase 4 51-74-1 65513
38 Amitriptyline, perphenazine drug combination Phase 4
39 Antipyretics Phase 4
40 Micronutrients Phase 4
41 Trace Elements Phase 4
42 Vitamins Phase 4
43 Nutrients Phase 4
44 Linoleate Phase 4
45 Angiotensinogen Phase 4
46 Giapreza Phase 4
47 Calciferol Phase 4
48 Vitamin B 12 Phase 4
49 Vitamin B12 Phase 4
50 Phosphodiesterase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 527)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
2 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
3 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
4 Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery Unknown status NCT02535000 Phase 4 Duloxetine;Placebo
5 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
6 Effects of Pregabalin on Mechanical Hyperalgesia - EPOM Unknown status NCT00310583 Phase 4 Pregabalin
7 Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
8 Attenuation of Spinal Induced Hypotension With Granisetron in Type I Diabetic Parturients Unknown status NCT03091881 Phase 4 Granisetron 0.1 MG/ML;Placebos
9 Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT00322621 Phase 4 Duloxetine
10 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
11 An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
12 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
13 A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride
14 An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
15 A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
16 A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain Completed NCT00904020 Phase 4 Lidoderm
17 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
18 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
19 Comparative Evaluation of Standard Wearing Shoes With Rocker Sole Shoes in Diabetic Patients With Neuropathy Completed NCT02891928 Phase 4
20 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
21 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
22 The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Patients With Diabetic Peripheral Neuropathic Pain: a Randomized, Placebo-controlled Study of South Asian Male Patients Completed NCT04238208 Phase 4 Lidocaine 5% patch;Capsaicin 8% Patch, Per 10 Square Centimeters
23 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
24 Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
25 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
26 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
27 Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading Completed NCT02439879 Phase 4 Alpha lipoic acid
28 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
29 A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
30 A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT02417935 Phase 4 Duloxetine;Pregabalin;Placebo
31 An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
32 PRELIMINARY EVALUATION OF RETINAL EFFECTS OF PHARMACOLOLOGICAL LOWERING OF SERUM LEVES OF ADVANCED GLYCATION END-PRODUCTS (AGEs) IN TYPE 2 DIABETIC PATIENTS Completed NCT02249897 Phase 4 CHOLESTYRAMINE
33 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
34 A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers Completed NCT01835379 Phase 4
35 An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
36 A Randomised, Controlled, Cross-over Study With Inpatient and Outpatient Phases Completed NCT01352767 Phase 4
37 Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
38 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
39 Open Labelled Study of Pregabalin in the Treatment of Neuropathic Pain in Cervical Myeloradiculopathy (Pregabalin and Radicular Pain Study (PARPS)) Completed NCT01061697 Phase 4 Pregabalin
40 Efficacy of Pregabalin in Patients With Radicular Pain Completed NCT00908375 Phase 4 Pregabalin;Sugar Pill
41 A Prospective, Open-label Trial of Lidoderm® (Lidocaine Patch 5%)in Painful Diabetic and Idiopathic Neuropathy. Completed NCT00903851 Phase 4 Lidoderm
42 Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
43 Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects Completed NCT02682901 Phase 4 Cycloset;Placebo
44 Gabapentin Kinetic Disposition and Renal Excretion: Role of Transporters for Organic Cations and the Effect of Glycemic Control in Patients With Neuropathic Pain. Completed NCT03047278 Phase 4 Gabapentin 300 mg;Cetirizine Hydrochloride 10 mg
45 A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
46 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4 Non-ARB (standard therapy);ARB (Telmisartan)
47 Dipeptidyl Peptidase (DPP) IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Patients With Type 2 Diabetes Completed NCT01472432 Phase 4 Placebo;vildagliptin
48 L-Arginine and Endothelial Dysfunction in Type 2 Diabetic Patients Completed NCT00902616 Phase 4
49 High-dose Vitamin D Supplementation Reduces Inflammation and Improves Microcirculation in Patients With Diabetic Peripheral Neuropathy Completed NCT04377399 Phase 4 Vitamin D
50 The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes Completed NCT00931879 Phase 4 omega-3-ethyl esters;Placebo

Search NIH Clinical Center for Diabetic Neuropathy

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Becaplermin
CAPSACIAN PWDR
Capsaicin
CAPSAICIN PWDR
Capsicum extract
CAPSICUM OLEORESIN
Citalopram
Citalopram hydrobromide
COBALAMIN CONCENTRATE
Hydroxocobalamin
HYDROXOCOBALAMIN ACETATE
mecobalamin
Mexiletine
Mexiletine Hydrochloride
Pentoxifylline
Vitamin B 12

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diabetic Neuropathy cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Diabetic Neuropathy:
Hematopoietic stem cells for limb ischemia and diabetic neuropathy
Embryonic/Adult Cultured Cells Related to Diabetic Neuropathy:
Peripheral blood-derived hematopoietic stem cells (family)

Genetic Tests for Diabetic Neuropathy

Anatomical Context for Diabetic Neuropathy

MalaCards organs/tissues related to Diabetic Neuropathy:

40
Testes, Skin, Spinal Cord, Endothelial, Heart, Bone, Brain

Publications for Diabetic Neuropathy

Articles related to Diabetic Neuropathy:

(show top 50) (show all 6758)
# Title Authors PMID Year
1
Transcriptomic analysis of glycan-processing genes in the dorsal root ganglia of diabetic mice and functional characterization on Cav3.2 channels. 61
32233724 2020
2
Selective Loss of Calretinin-Poor Cochlear Afferent Nerve Fibers in Streptozotocin-Induced Hyperglycemic Mice. 61
32331128 2020
3
Beneficial effects of ferulic acid alone and in combination with insulin in streptozotocin induced diabetic neuropathy in Sprague Dawley rats. 61
32473246 2020
4
Intraocular pressure fluctuation and neurodegeneration in the diabetic rat retina. 61
32087615 2020
5
Agomelatine potentiates anti-nociceptive effects of morphine in a mice model for diabetic neuropathy: involvement of NMDA receptor subtype NR1 within the raphe nucleus and periaqueductal grey. 61
32336224 2020
6
Adrenomedullin: an important participant in neurological diseases. 61
31960799 2020
7
Treatment of diabetic peripheral neuropathy: a review. 61
32067247 2020
8
Treatment induced neuropathy of diabetes. 61
32247944 2020
9
Sodium nitrate preconditioning prevents progression of the neuropathic pain in streptozotocin-induced diabetes Wistar rats. 61
32550160 2020
10
Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study. 61
32576561 2020
11
Duloxetine ameliorates the impairment of diffuse noxious inhibitory control in rat models of peripheral neuropathic pain and knee osteoarthritis pain. 61
32315711 2020
12
Effect of different exercise training intensities on musculoskeletal and neuropathic pain in inactive individuals with type 2 diabetes - Preliminary randomised controlled trial. 61
32360399 2020
13
Associations Between General and Abdominal Obesity and Incident Diabetic Neuropathy in Participants with Type 2 Diabetes Mellitus. 61
32500961 2020
14
Neglected foreign body in the foot of a patient with severe diabetic neuropathy. 61
32554454 2020
15
Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ. 61
32184124 2020
16
The association of periodontal disease with the complications of diabetes mellitus. A systematic review. 61
32526263 2020
17
Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature. 61
32483988 2020
18
Diagnosis Accuracy of Carpal Tunnel Syndrome in Diabetic Neuropathy. 61
32517033 2020
19
The protective effects of moscatilin against methylglyoxal-induced neurotoxicity via the regulation of p38/JNK MAPK pathways in PC12 neuron-like cells. 61
32325188 2020
20
Botulinum neurotoxin injections for muscle-based (dystonia and spasticity) and non-muscle-based (neuropathic pain) pain disorders: a meta-analytic study. 61
32146504 2020
21
Statins and Neuropathic Pain: A Narrative Review. 61
32020545 2020
22
Footwear and insole design features that reduce neuropathic plantar forefoot ulcer risk in people with diabetes: a systematic literature review. 61
32498719 2020
23
Mini Invasive Floating Metatarsal Osteotomy for Diabetic Foot Ulcers Under the First Metatarsal Head: A Case Series. 61
32552348 2020
24
Dexmedetomidine exerts neuroprotective effects during high glucose-induced neural injury by inhibiting miR-125b. 61
32538430 2020
25
The Effectiveness of Acceptance and Commitment Therapy on Pain Acceptance and Pain Perception in Patients with Painful Diabetic Neuropathy: A Randomized Controlled Trial. 61
32533548 2020
26
The impact of sensory and/or sensorimotor neuropathy on lower limb muscle endurance, explosive and maximal muscle strength in patients with type 2 diabetes mellitus. 61
32122790 2020
27
Lumbar sympathetic pulsed radiofrequency combined with continuous epidural infusion for treatment of painful diabetic neuropathy: A report of two cases and a literature review. 61
32521585 2020
28
Comorbid Conditions and GFR Predict Nonvertebral Fractures in Patients With Diabetes in an Ethnic-Specific Manner. 61
32193529 2020
29
Inhibition of PI3K/AKT/mTOR signaling pathway promotes autophagy and relieves hyperalgesia in diabetic rats. 61
32427714 2020
30
Hand and foot exercises for diabetic peripheral neuropathy: A randomized controlled trial. 61
31876991 2020
31
Formononetin Ameliorates Diabetic Neuropathy by Increasing Expression of SIRT1 and NGF. 61
32459048 2020
32
A Secondary Analysis from a Randomized Trial on the Effect of Plasma Tetrahydrocannabinol Levels on Pain Reduction in Painful Diabetic Peripheral Neuropathy. 61
32565122 2020
33
The bone marrow-derived mesenchymal stem cells (BMSCs) alleviate diabetic peripheral neuropathy induced by STZ via activating GSK-3β/β-catenin signaling pathway. 61
32502517 2020
34
The effects of a supportive-educational intervention on women with type 2 diabetes and diabetic peripheral neuropathy: a randomized controlled trial. 61
32306762 2020
35
Experience of patisiran with transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis. 61
32519928 2020
36
Bardoxolone Methyl Ameliorates Hyperglycemia Induced Mitochondrial Dysfunction by Activating the keap1-Nrf2-ARE Pathway in Experimental Diabetic Neuropathy. 61
32556916 2020
37
Regular Use of FlowAid FA100 SCCD Reduces Pain While Increasing Perfusion and Tissue Oxygenation in Contralateral Limbs of Amputees With Diabetic Neuropathy and Peripheral Arterial Disease: Results of an Open, Pre-Post Intervention, Single-Center Study. 61
32525719 2020
38
The neuroprotective effect and action mechanism of polyphenols in diabetes mellitus-related cognitive dysfunction. 61
31598747 2020
39
Vitamin D Deficiency is Associated With Painful Diabetic Neuropathy. 61
32506740 2020
40
Modeling Hypoxia-Induced Neuropathies Using a Fast and Scalable Human Motor Neuron Differentiation System. 61
32386561 2020
41
Neuroprotective effects of isoquercitrin in diabetic neuropathy via Wnt/β-catenin signaling pathway inhibition. 61
31960520 2020
42
The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial. 61
32456230 2020
43
Inter-joint coordination during obstacle crossing in people with diabetic neuropathy. 61
32307183 2020
44
Diabetic neuropathy: what does the future hold? 61
31974731 2020
45
Global Disability Burdens of Diabetes-Related Lower-Extremity Complications in 1990 and 2016. 61
32139380 2020
46
Naringenin ameliorates diabetic neuropathic pain by modulation of oxidative-nitrosative stress, cytokines and MMP-9 levels. 61
32400767 2020
47
Simulation Study to Estimate Bias of Treatment Effect in Pain Scores in Diabetic Neuropathy. 61
31504888 2020
48
Prevalence and management of diabetic neuropathy in secondary care in Qatar. 61
31913560 2020
49
Online Acceptance and Commitment Therapy for People with Painful Diabetic Neuropathy in the United Kingdom: A Single-Arm Feasibility Trial. 61
32358608 2020
50
Effects of hydrotherapy with massage on serum nerve growth factor concentrations and balance in middle aged diabetic neuropathy patients. 61
32379676 2020

Variations for Diabetic Neuropathy

Expression for Diabetic Neuropathy

Search GEO for disease gene expression data for Diabetic Neuropathy.

Pathways for Diabetic Neuropathy

Pathways related to Diabetic Neuropathy according to KEGG:

36
# Name Kegg Source Accession
1 AGE-RAGE signaling pathway in diabetic complications hsa04933

GO Terms for Diabetic Neuropathy

Cellular components related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 VEGFA NTF3 NGF LEP INS GDNF
2 axon GO:0030424 9.55 SCN9A NTRK1 NTF3 NGF CALCA
3 extracellular space GO:0005615 9.4 VEGFA SORD NTF3 NGF LEP INS

Biological processes related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.02 VEGFA NTF3 LEP INS GDNF EPO
2 inflammatory response GO:0006954 10 TRPV1 TLR4 SCN9A CALCA AGER
3 positive regulation of cell migration GO:0030335 9.95 VEGFA SOD2 NTF3 INS
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 TLR4 NTRK1 EPO AGER
5 positive regulation of protein phosphorylation GO:0001934 9.91 VEGFA NTRK1 LEP AGER
6 aging GO:0007568 9.89 NTRK1 EPO CAT CALCA
7 positive regulation of cold-induced thermogenesis GO:0120162 9.85 VEGFA TRPM8 LEP
8 response to hypoxia GO:0001666 9.85 VEGFA LEP EPO CAT AGER
9 activation of protein kinase activity GO:0032147 9.84 VEGFA EPO CALCA
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 VEGFA NTF3 NGF
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.82 VEGFA LEP EPO
12 cellular response to growth factor stimulus GO:0071363 9.81 TRPV1 NTRK1 CAT
13 response to nutrient levels GO:0031667 9.8 SORD NTRK1 LEP
14 glucose metabolic process GO:0006006 9.79 SORD LEP INS
15 sensory perception of pain GO:0019233 9.77 TRPV1 SCN9A NTRK1
16 cellular response to amyloid-beta GO:1904646 9.75 TLR4 NTRK1 AGER
17 cellular response to nerve growth factor stimulus GO:1990090 9.73 TRPV1 NTRK1 CALCA
18 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.72 TLR4 NTRK1 INS CAT AGER
19 regulation of blood pressure GO:0008217 9.71 SOD2 LEP CALCA ACE
20 positive regulation of Ras protein signal transduction GO:0046579 9.7 NTRK1 NGF EPO
21 positive regulation of p38MAPK cascade GO:1900745 9.69 VEGFA LEP AGER
22 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.66 SOD2 INS
23 behavioral response to pain GO:0048266 9.66 TRPV1 SCN9A
24 commissural neuron axon guidance GO:0071679 9.65 VEGFA GDNF
25 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.65 TRPV1 NTRK1 CALCA
26 negative regulation of neuron apoptotic process GO:0043524 9.65 SOD2 NTRK1 NTF3 NGF GDNF
27 response to vitamin E GO:0033197 9.63 LEP CAT
28 induction of positive chemotaxis GO:0050930 9.61 VEGFA NTF3 AGER
29 negative regulation of calcium ion transport into cytosol GO:0010523 9.58 EPO CALCA
30 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.57 VEGFA ACE
31 negative regulation of apoptotic process GO:0043066 9.56 VEGFA NTRK1 NGF LEP GDNF EPO
32 thermoception GO:0050955 9.54 TRPV1 TRPM8
33 nerve growth factor signaling pathway GO:0038180 9.54 NTRK1 NTF3 NGF
34 fructose biosynthetic process GO:0046370 9.49 SORD AKR1B1
35 peripheral nervous system development GO:0007422 9.46 PMP22 NTF3 NGF GDNF
36 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.1 NTRK1 NTF3 LEP INS EPO CAT

Molecular functions related to Diabetic Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.56 VEGFA NTF3 NGF GDNF
2 hormone activity GO:0005179 9.46 LEP INS EPO CALCA
3 signaling receptor binding GO:0005102 9.43 TLR4 NTF3 NGF LEP GDNF CALCA
4 identical protein binding GO:0042802 9.36 VEGFA TRPV1 TRPM8 TLR4 SORD SOD2
5 nerve growth factor receptor binding GO:0005163 9.32 NTF3 NGF

Sources for Diabetic Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....